|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
The International Agency for Research on
Cancer: GLOBOCAN 2020: New Global Cancer Data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
Accessed December 17 2020
|
|
3
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé
S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and
mortality of cervical cancer in 2018: A worldwide analysis. Lancet
Glob Health. 8:e191–203. 2020. View Article : Google Scholar :
|
|
4
|
Falcaro M, Castañon A, Ndlela B, Checchi
M, Soldan K, Lopez-Bernal J, Elliss-Brookes L and Sasieni P: The
effects of the national HPV vaccination programme in England, UK,
on cervical cancer and grade 3 cervical intraepithelial neoplasia
incidence: A register-based observational study. Lancet.
398:2084–2092. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moscicki AB, Schiffman M, Burchell A,
Albero G, Giuliano AR, Goodman MT, Kjaer SK and Palefsky J:
Updating the natural history of human papillomavirus and anogenital
cancers. Vaccine. 30(Suppl 5): F24–F33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tommasino M: The human papillomavirus
family and its role in carcinogenesis. Semin Cancer Biol. 26:13–21.
2014. View Article : Google Scholar
|
|
7
|
Hammer A, Rositch A, Qeadan F, Gravitt PE
and Blaakaer J: Age-specific prevalence of HPV16/18 genotypes in
cervical cancer: A systematic review and meta-analysis. Int J
Cancer. 138:2795–2803. 2016. View Article : Google Scholar
|
|
8
|
Wright JD, Matsuo K, Huang Y, Tergas AI,
Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI and
Hershman DL: Prognostic performance of the 2018 international
federation of gynecology and obstetrics cervical cancer staging
guidelines. Obstet Gynecol. 134:49–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Juan A, Redondo A, Rubio MJ, García Y,
Cueva J, Gaba L, Yubero A, Alarcón J, Maximiano C and Oaknin A:
SEOM clinical guidelines for cervical cancer (2019). Clin Transl
Oncol. 22:270–278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu SC, Huang EY, Hu CF, Ou YC, ChangChien
CC, Wang CJ, Tsai CC, Fu HC, Wu CH and Lin H: Pretreatment factors
associated with recurrence for patients with cervical cancer
international federation of gynecology and obstetrics stage IB1
disease. Gynecol Obstet Invest. 81:339–345. 2016. View Article : Google Scholar
|
|
11
|
Rodriguez NM: Participatory innovation for
human papillomavirus screening to accelerate the elimination of
cervical cancer. Lancet Glob Health. 9:e582–e583. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou J, Lei N, Tian W, Guo R, Chen M, Qiu
L, Wu F, Li Y and Chang L: Recent progress of the tumor
microenvironmental metabolism in cervical cancer radioresistance.
Front Oncol. 12:9996432022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Cai H, Xiao ZX, Wang H and Yang P:
Effect of radiotherapy on the survival of cervical cancer patients:
An analysis based on SEER database. Medicine (Baltimore).
98:e164212019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
U.S. Food and Drug Administration: About
Biomarkers and Qualification. https://www.fda.gov/drugs/biomarker-qualificationprogram/about-biomarkers-and-qualification.
Accessed July 7, 2021
|
|
15
|
Volkova LV, Pashov AI and Omelchuk NN:
Cervical Carcinoma: Oncobiology and Biomarkers. Int J Mol Sci.
22:125712021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ballman KV: Biomarker: Predictive or
Prognostic? J Clin Oncol. 33:3968–3971. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yusufaly TI, Zou J, Nelson TJ, Williamson
CW, Simon A, Singhal M, Liu H, Wong H, Saenz CC, Mayadev J, et al:
Improved Prognosis of Treatment Failure in Cervical Cancer with
Nontumor PET/CT Radiomics. J Nucl Med. 63:1087–1093. 2022.
View Article : Google Scholar :
|
|
18
|
Chang R, Qi S, Yue Y, Zhang X, Song J and
Qian W: Predictive radiomic models for the chemotherapy response in
non-small-cell lung cancer based on computerized-tomography images.
Front Oncol. 11:6461902021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dhama K, Latheef SK, Dadar M, Samad HA,
Munjal A, Khandia R, Karthik K, Tiwari R, Yatoo MI, Bhatt P, et al:
Biomarkers in stress related diseases/disorders: diagnostic,
prognostic, and therapeutic values. Front Mol Biosci. 6:912019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang LH, Wu CF, Rajasekaran N and Shin YK:
Loss of tumor suppressor gene function in human cancer: An
overview. Cell Physiol Biochem. 51:2647–2693. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tornesello ML, Faraonio R, Buonaguro L,
Annunziata C, Starita N, Cerasuolo A, Pezzuto F, Tornesello AL and
Buonaguro FM: The Role of microRNAs, Long Non-coding RNAs, and
Circular RNAs in Cervical Cancer. Front Oncol. 10:1502020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gyparaki MT, Basdra EK and Papavassiliou
AG: DNA methylation biomarkers as diagnostic and prognostic tools
in colorectal cancer. J Mol Med (Berl). 91:1249–1256. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Charakorn C, Thadanipon K, Chaijindaratana
S, Rattanasiri S, Numthavaj P and Thakkinstian A: The association
between serum squamous cell carcinoma antigen and recurrence and
survival of patients with cervical squamous cell carcinoma: A
systematic review and meta-analysis. Gynecol Oncol. 150:190–200.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dixit CK, Kadimisetty K, Otieno BA, Tang
C, Malla S, Krause CE and Rusling JF: Electrochemistry-based
approaches to low cost, high sensitivity, automated, multiplexed
protein immunoassays for cancer diagnostics. Analyst. 141:536–547.
2016. View Article : Google Scholar :
|
|
25
|
Füzéry AK, Levin J, Chan MM and Chan DW:
Translation of proteomic biomarkers into FDA approved cancer
diagnostics: Issues and challenges. Clin Proteomics. 10:132013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun Z, Shi Y, Shen Y, Cao L, Zhang W and
Guan X: Analysis of different HER-2 mutations in breast cancer
progression and drug resistance. J Cell Mol Med. 19:2691–2701.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang Y, Zhang H, Zhang M, Meng Q, Cai L
and Zhang Q: Elevation of serum CEA and CA15-3 levels during
antitumor therapy predicts poor therapeutic response in advanced
breast cancer patients. Oncol Lett. 14:7549–7556. 2017.
|
|
28
|
Alegría-Baños JA, Jiménez-López JC,
Vergara-Castañeda A, de León DFC, Mohar-Betancourt A, Pérez-Montiel
D, Sánchez-Domínguez G, García-Villarejo M, Olivares-Pérez C,
Hernández-Constantino Á, et al: Kinetics of HE4 and CA125 as
prognosis biomarkers during neoadjuvant chemotherapy in advanced
epithelial ovarian cancer. J Ovarian Res. 14:962021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Islam MS, Afrin S, Jones SI and Segars J:
Selective progesterone receptor modulators-mechanisms and
therapeutic utility. Endocr Rev. 41:bnaa0122020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duffy MJ, Harbeck N, Nap M, Molina R,
Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in
breast cancer: Updated guidelines from the European Group on Tumor
Markers (EGTM). Eur J Cancer. 75:284–298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chimento A, De Luca A, Avena P, De Amicis
F, Casaburi I, Sirianni R and Pezzi V: Estrogen receptors-mediated
apoptosis in hormone-dependent cancers. Int J Mol Sci. 23:12422022.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seale KN and Tkaczuk KHR: Circulating
biomarkers in breast cancer. Clin Breast Cancer. 22:e319–e331.
2022. View Article : Google Scholar
|
|
33
|
Banerjee S, Yoon H, Ting S, Tang CM, Yebra
M, Wenzel AT, Yeerna H, Mesirov JP, Wechsler-Reya RJ, Tamayo P and
Sicklick JK: KITlow cells mediate imatinib resistance in
gastrointestinal stromal tumor. Mol Cancer Ther. 20:2035–2048.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jing W, Zhang R, Chen X, Zhang X and Qiu
J: Association of glycosylation-related genes with different
patterns of immune profiles and prognosis in cervical cancer. J
Pers Med. 13:5292023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
National center for Biotechnology
Information. https://clinicaltrials.gov/. 2023, Clinicaltrials.gov.
|
|
36
|
Hishinuma E, Shimada M, Matsukawa N, Li B,
Motoike IN, Hagihara T, Shigeta S, Tokunaga H, Saigusa D, Kinoshita
K, et al: Identification of predictive biomarkers for diagnosis and
radiation sensitivity of uterine cervical cancer using
wide-targeted metabolomics. J Obstet Gynaecol Res. 49:2109–2117.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kilic S, Cracchiolo B, Gabel M, Haffty B
and Mahmoud O: The relevance of molecular biomarkers in cervical
cancer patients treated with radiotherapy. Ann Transl Med.
3:2612015.PubMed/NCBI
|
|
38
|
Rashid M, Zadeh LR, Baradaran B, Molavi O,
Ghesmati Z, Sabzichi M and Ramezani F: Up-down regulation of HIF-1α
in cancer progression. Gene. 798:1457962021. View Article : Google Scholar
|
|
39
|
Le QT and Courter D: Clinical biomarkers
for hypoxia targeting. Cancer Metastasis Rev. 27:351–362. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bishop AJ, Allen PK, Klopp AH, Meyer LA
and Eifel PJ: Relationship Between Low Hemoglobin Levels and
Outcomes After Treatment With Radiation or Chemoradiation in
Patients With Cervical Cancer: Has the Impact of Anemia Been
Overstated? Int J Radiat Oncol Biol Phys. 91:196–205. 2015.
View Article : Google Scholar
|
|
41
|
Airley RE, Loncaster J, Raleigh JA, Harris
AL, Davidson SE, Hunter RD, West CM and Stratford IJ: GLUT-1 and
CAIX as intrinsic markers of hypoxia in carcinoma of the cervix:
Relationship to pimonidazole binding. Int J Cancer. 104:85–91.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Feldser D, Agani F, Iyer NV, Pak B,
Ferreira G and Semenza GL: Reciprocal positive regulation of
hypoxia-inducible factor 1alpha and insulin-like growth factor 2.
Cancer Res. 59:3915–3938. 1999.PubMed/NCBI
|
|
43
|
Domènech M, Hernández A, Plaja A,
Martínez-Balibrea E and Balañà C: Hypoxia: The cornerstone of
glioblastoma. Int J Mol Sci. 22:126082021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lei R, Li J, Liu F, Li W, Zhang S, Wang Y,
Chu X and Xu J: HIF-1α promotes the keloid development through the
activation of TGF-beta/Smad and TLR4/MyD88/NF-kappaB pathways. Cell
Cycle. 18:3239–3250. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang PC, Liu X, Li MM, Ma YY, Sun HT,
Tian XY, Wang Y, Liu M, Fu LS, Wang YF, et al: AT-533, a novel
Hsp90 inhibitor, inhibits breast cancer growth and
HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Biochem Pharmacol. 172:1137712020. View Article : Google Scholar
|
|
46
|
Apte RS, Chen DS and Ferrara N: VEGF in
signaling and disease: Beyond discovery and development. Cell.
176:1248–1264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoshida K, Suzuki S, Sakata J, Utsumi F,
Niimi K, Yoshikawa N, Nishino K, Shibata K, Kikkawa F and Kajiyama
H: The upregulated expression of vascular endothelial growth factor
in surgically treated patients with recurrent/radioresistant
cervical cancer of the uterus. Oncol Lett. 16:515–521.
2018.PubMed/NCBI
|
|
48
|
Yan B, Ma QF, Tan WF, Cai HN, Li YL, Zhou
ZG, Dai X, Zhu FX, Xiong YJ, Xu M, et al: Expression of HIF-1α is a
predictive marker of the efficacy of neoadjuvant chemotherapy for
locally advanced cervical cancer. Oncol Lett. 20:841–849. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hu X, Xing L, Wei X, Liu X, Pang R, Qi L
and Song S: Nonangiogenic function of VEGF and enhanced
radiosensitivity of HeLa cells by inhibition of VEGF expression.
Oncol Res. 20:93–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhu P, Ou Y, Dong Y, Xu P and Yuan L:
Expression of VEGF and HIF-1α in locally advanced cervical cancer:
potential biomarkers for predicting preoperative radiochemotherapy
sensitivity and prognosis. Onco Targets Ther. 9:3031–3037.
2016.
|
|
51
|
Wei LC, Wang N, Shi M, Liu JY, Li JP,
Zhang Y, Huang YH, Li X and Chen Y: Clinical outcome observation of
preoperative concurrent chemoradiotherapy/radiotherapy alone in 174
Chinese patients with local advanced cervical carcinoma. Onco
Targets Ther. 6:67–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ferrandina G, Legge F, Fagotti A, Fanfani
F, Distefano M, Morganti A, Cellini N and Scambia G: Preoperative
concomitant chemoradiotherapy in locally advanced cervical cancer:
Safety, outcome, and prognostic measures. Gynecol Oncol. 107(1
Suppl 1): S127–S132. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lèguevaque P, Motton S, Delannes M,
Querleu D, Soulé-Tholy M, Tap G and Houvenaeghel G: Completion
surgery or not after concurrent chemoradiotherapy for locally
advanced cervical cancer? Eur J Obstet Gynecol Reprod Biol.
155:188–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sharma M, Khan R, Aggarwal M and Sharma A:
Modulatory effects of chemoradiation on angiogenic factors and
laminin in cervical cancer: Link with treatment response. Asian Pac
J Cancer Prev. 18:2937–2944. 2017.PubMed/NCBI
|
|
55
|
Nguyen VT, Winterman S, Playe M, Benbara
A, Zelek L, Pamoukdjian F and Bousquet G: Dose-Intense
cisplatin-based neoadjuvant chemotherapy increases survival in
advanced cervical cancer: An up-to-date meta-analysis. Cancers
(Basel). 14:8422022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Angioli R, Plotti F, Montera R, Aloisi A,
Luvero D, Capriglione S, Terranova C, De Cicco Nardone C, Muzii L
and Benedetti-Panici P: Neoadjuvant chemotherapy plus radical
surgery followed by chemotherapy in locally advanced cervical
cancer. Gynecol Oncol. 127:290–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhao K, Hu M, Yang R, Liu J, Zeng P and
Zhao T: Decreasing expression of HIF-1α, VEGF-A, and Ki67 with
efficacy of neoadjuvant therapy in locally advanced cervical
cancer. Medicine (Baltimore). 102:e338202023. View Article : Google Scholar
|
|
58
|
Hu Y, Han Y, Shen Y, Chen J, Chen Y, Chen
Y, Tang J, Xue M, Hong L, Cheng W, et al: Neoadjuvant chemotherapy
for patients with international federation of gynecology and
obstetrics stages IB3 and IIA2 cervical cancer: A multicenter
prospective trial. BMC Cancer. 202:12702022. View Article : Google Scholar
|
|
59
|
Datta A, West C, O'Connor JPB, Choudhury A
and Hoskin P: Impact of hypoxia on cervical cancer outcomes. Int J
Gynecol Cancer. 31:1459–1470. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dunst J, Kuhnt T, Strauss HG, Krause U,
Pelz T, Koelbl H and Haensgen G: Anemia in cervical cancers: Impact
on survival, patterns of relapse, and association with hypoxia and
angiogenesis. Int J Radiat Oncol Biol Phys. 56:778–787. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shin NR, Lee YY, Kim SH, Choi CH, Kim TJ,
Lee JW, Bae DS and Kim BG: Prognostic value of pretreatment
hemoglobin level in patients with early cervical cancer. Obstet
Gynecol Sci. 57:28–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Barkati M, Fortin I, Mileshkin L, Bernshaw
D, Carrier JF and Narayan K: Hemoglobin level in cervical cancer: a
surrogate for an infiltrative phenotype. Int J Gynecol Cancer.
23:724–729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gennigens C, De Cuypere M, Seidel L,
Hermesse J, Barbeaux A, Forget F, Albert A, Jerusalem G and
Kridelka F: Correlation between hematological parameters and
outcome in patients with locally advanced cervical cancer treated
by concomitant chemoradiotherapy. Cancer Med. 9:8432–8443. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Moreno-Acosta P, Carrillo S, Gamboa O,
Romero-Rojas A, Acosta J, Molano M, Balart-Serra J, Cotes M,
Rancoule C and Magné N: Novel predictive biomarkers for cervical
cancer prognosis. Mol Clin Oncol. 5:792–796. 2016. View Article : Google Scholar
|
|
65
|
Kasi PM and Grothey A:
Chemotherapy-Induced neutropenia as a prognostic and predictive
marker of outcomes in solid-tumor patients. Drugs. 78:737–745.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Markovina S, Wang S, Henke LE, Luke CJ,
Pak SC, DeWees T, Pfeifer JD, Schwarz JK, Liu W, Chen S, et al:
Serum squamous cell carcinoma antigen as an early indicator of
response during therapy of cervical cancer. Br J Cancer. 118:72–78.
2018. View Article : Google Scholar :
|
|
67
|
Chen W, Xiu S, Xie X, Guo H, Xu Y, Bai P
and Xia X: Prognostic value of tumor measurement parameters and
SCC-Ag changes in patients with locally-advanced cervical cancer.
Radiat Oncol. 17:62022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Choi KH, Lee SW, Yu M, Jeong S, Lee JW and
Lee JH: Significance of elevated SCC-Ag level on tumor recurrence
and patient survival in patients with squamous-cell carcinoma of
uterine cervix following definitive chemoradiotherapy: A
multi-institutional analysis. J Gynecol Oncol. 30:e12019.
View Article : Google Scholar
|
|
69
|
Xu D, Wang D, Wang S, Tian Y, Long Z and
Ren X: Correlation between squamous cell carcinoma antigen level
and the clinicopathological features of early-stage cervical
squamous cell carcinoma and the predictive value of squamous cell
carcinoma antigen combined with computed tomography scan for lymph
node metastasis. Int J Gynecol Cancer. 27:1935–1942. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tantari M, Bogliolo S, Morotti M, Balaya
V, Bouttitie F, Buenerd A, Magaud L, Lecuru F, Guani B, Mathevet P,
et al: Lymph node involvement in early-stage cervical cancer: Is
lymphangiogenesis a risk factor? Results from the MICROCOL Study.
Cancers (Basel). 14:2122022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kang S, Nam BH, Park JY, Seo SS, Ryu SY,
Kim JW, Kim SC, Park SY and Nam JH: Risk Assessment tool for
distant recurrence after platinum-based concurrent chemoradiation
in patients with locally advanced cervical cancer: A Korean
gynecologic oncology group study. J Clin Oncol. 30:2369–2374. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mabuchi S, Isohashi F, Yokoi T, Takemura
M, Yoshino K, Shiki Y, Ito K, Enomoto T, Ogawa K and Kimura T: A
phase II study of postoperative concurrent carboplatin and
paclitaxel combined with intensity-modulated pelvic radiotherapy
followed by consolidation chemotherapy in surgically treated
cervical cancer patients with positive pelvic lymph nodes. Gynecol
Oncol. 141:240–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shim SH, Kim DY, Lee SJ, Kim SN, Kang SB,
Lee SW, Park JY, Suh DS, Kim JH, Kim YM, et al: Prediction model
for para-aortic lymph node metastasis in patients with locally
advanced cervical cancer. Gynecol Oncol. 144:40–45. 2017.
View Article : Google Scholar
|
|
74
|
Yoon HI, Cha J, Keum KC, Lee HY, Nam EJ,
Kim SW, Kim S, Kim YT, Kim GE and Kim YB: Treatment outcomes of
extended-field radiation therapy and the effect of concurrent
chemotherapy on uterine cervical cancer with para-aortic lymph node
metastasis. Radiat Oncol. 10:182015. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang G, Fu C, Zhang Y, Wang J, Qiao N,
Yang Q and Cheng Y: Extended-Field Intensity-Modulated Radiotherapy
and Concurrent Cisplatin-Based Chemotherapy for Postoperative
Cervical Cancer With Common Iliac or Para-Aortic Lymph Node
Metastases: A Retrospective Review in a Single Institution. Int J
Gynecol Cancer. 22:1220–1225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Walker JL, Morrison A, DiSilvestro P and
von Gruenigen VE; Gynecologic Oncology Group: A phase I/II study of
extended field radiation therapy with concomitant paclitaxel and
cisplatin chemotherapy in patients with cervical carcinoma
metastatic to the para-aortic lymph nodes: A gynecologic oncology
group study. Gynecol Oncol. 112:78–84. 2009. View Article : Google Scholar
|
|
77
|
Matsuo K, Shimada M, Aoki Y, Sakamoto M,
Takeshima N, Fujiwara H, Matsumoto T, Mikami M and Sugiyama T:
Comparison of adjuvant therapy for node-positive clinical stage
IB-IIB cervical cancer: Systemic chemotherapy versus pelvic
irradiation. Int J Cancer. 141:1042–1051. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Jung PS, Kim DY, Lee SW, Park JY, Suh DS,
Kim JH, Kim YM, Kim YT and Nam JH: clinical role of adjuvant
chemotherapy after radical hysterectomy for FIGO Stage IB-IIA
cervical cancer: Comparison with Adjuvant RT/CCRT using
inverse-probability-of-treatment weighting. PLoS One.
10:e01322982015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Strauss HG, Laban C, Lautenschläger C,
Buchmann J, Schneider I and Koelbl H: SCC antigen in the serum as
an independent prognostic factor in operable squamous cell
carcinoma of the cervix. Eur J Cancer. 38:1987–1991. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhang G, Miao L, Wu H, Zhang Y and Fu C:
Pretreatment squamous cell carcinoma antigen (SCC-Ag) as a
predictive factor for the use of consolidation chemotherapy in
cervical cancer patients after postoperative extended-field
concurrent chemoradiotherapy. Technol Cancer Res Treat.
20:153303382110446262021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kawaguchi R, Furukawa N, Kobayashi H and
Asakawa I: Posttreatment cut-off levels of squamous cell carcinoma
antigen as a prognostic factor in patients with locally advanced
cervical cancer treated with radiotherapy. J Gynecol Oncol.
24:313–320. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ryu HK, Baek JS, Kang WD and Kim SM: The
prognostic value of squamous cell carcinoma antigen for predicting
tumor recurrence in cervical squamous cell carcinoma patients.
Obstet Gynecol Sci. 58:368–376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Gadducci A, Tana R, Cosio S and Genazzani
AR: The serum assay of tumour markers in the prognostic evaluation,
treatment monitoring and follow-up of patients with cervical
cancer: A review of the literature. Crit Rev Oncol Hematol.
66:10–20. 2008. View Article : Google Scholar
|
|
84
|
Jiang M, Chen P, Guo X, Zhang X, Gao Q,
Zhang J, Zhao G and Zheng J: Identification of EGFR mutation status
in male patients with non-small-cell lung cancer: Role of 18F-FDG
PET/CT and serum tumor markers CYFRA21-1 and SCC-Ag. EJNMMI Res.
13:272023. View Article : Google Scholar :
|
|
85
|
Liu Z and Shi H: Prognostic role of
squamous cell carcinoma antigen in cervical cancer: A
Meta-analysis. Dis Markers. 2019:67103522019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Anastasi E, Gigli S, Ballesio L, Angeloni
A and Manganaro L: The complementary role of imaging and tumor
biomarkers in gynecological cancers: An update of the literature.
Asian Pac J Cancer Prev. 19:309–317. 2018.PubMed/NCBI
|
|
87
|
Cortés-Ciriano I, Lee JJK, Xi R, Jain D,
Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS, et
al: Comprehensive analysis of chromothripsis in 2,658 human cancers
using whole-genome sequencing. Nat Genet. 52:331–341. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Müller D and Győrffy B: DNA
methylation-based diagnostic, prognostic, and predictive biomarkers
in colorectal cancer. Biochim Biophys Acta Rev Cancer.
1877:1887222022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
He L, Zhao C, Zhang Q, Zinta G, Wang D,
Lozano-Durán R and Zhu JK: Pathway conversion enables a double-lock
mechanism to maintain DNA methylation and genome stability. Proc
Natl Acad Sci USA. 118:e21073201182021. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Portela A and Esteller M: Epigenetic
modifications and human disease. Nat Biotechnol. 28:1057–1068.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Vural S, Palmisano A, Reinhold WC, Pommier
Y, Teicher BA and Krushkal J: Association of expression of
epigenetic molecular factors with DNA methylation and sensitivity
to chemotherapeutic agents in cancer cell lines. Clin Epigenetics.
13:492021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Xing W, Sun H, Yan C, Zhao C, Wang D, Li M
and Ma J: A prediction model based on DNA methylation biomarkers
and radiological characteristics for identifying malignant from
benign pulmonary nodules. BMC Cancer. 21:2632021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Levenson VV: DNA methylation as a
universal biomarker. Expert Rev Mol Diagn. 10:481–488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Locke WJ, Guanzon D, Ma C, Liew YJ,
Duesing KR, Fung KYC and Ross JP: DNA Methylation cancer
biomarkers: Translation to the Clinic. Front Genet. 10:11502019.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Clarke MA, Luhn P, Gage JC, Bodelon C,
Dunn ST, Walker J, Zuna R, Hewitt S, Killian JK, Yan L, et al:
Discovery and validation of candidate host DNA methylation markers
for detection of cervical precancer and cancer. Int J Cancer.
141:701–710. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
El Aliani A, El-Abid H, El Mallali Y,
Attaleb M, Ennaji MM and El Mzibri M: Association between Gene
Promoter Methylation and Cervical Cancer Development: Global
Distribution and A Meta-analysis. Cancer Epidemiol Biomarkers Prev.
30:450–459. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Liu J, Nie S, Li S, Meng H, Sun R, Yang J
and Cheng W: Methylation-driven genes and their prognostic value in
cervical squamous cell carcinoma. Ann Transl Med. 8:868. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Salta S, Maia-Moço L, Estevão-Pereira H,
Sequeira JP, Vieira R, Bartosch C, Petronilho S, Monteiro P, Sousa
A, Baldaque I, et al: Performance of DNA methylation-based
biomarkers in the cervical cancer screening program of northern
Portugal: A feasibility study. Int J Cancer. 149:1916–1925. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Verhoef VM, Bosgraaf RP, van Kemenade FJ,
Rozendaal L, Heideman DAM, Hesselink AT, Bekkers RL, Steenbergen
RD, Massuger LF, Melchers WJ, et al: Triage by methylation-marker
testing versus cytology in women who test HPV-positive on
self-collected cervicovaginal specimens (PROHTECT-3): A randomised
controlled non-inferiority trial. Lancet Oncol. 15:315–322. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sood S, Patel FD, Ghosh S, Arora A,
Dhaliwal LK and Srinivasan R: Epigenetic Alteration by DNA
Methylation of ESR1, MYOD1 and hTERT gene promoters is useful for
prediction of response in patients of locally advanced invasive
cervical carcinoma treated by chemoradiation. Clin Oncol (R Coll
Radiol). 27:720–727. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Contreras-Romero C, Pérez-Yépez EA,
Martinez-Gutierrez AD, Campos-Parra A, Zentella-Dehesa A,
Jacobo-Herrera N, López-Camarillo C, Corredor-Alonso G,
Martínez-Coronel J, Rodríguez-Dorantes M, et al: Gene
Promoter-Methylation signature as biomarker to predict
cisplatin-radiotherapy sensitivity in locally advanced cervical
cancer. Front Oncol. 12:7734382022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Guerrero-Setas D, Pérez-Janices N,
Blanco-Fernandez L, Ojer A, Cambra K, Berdasco M, Esteller M,
Maria-Ruiz S, Torrea N and Guarch R: RASSF2 hypermethylation is
present and related to shorter survival in squamous cervical
cancer. Mod Pathol. 26:1111–1122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yamazaki Y, Ur rutia R, Franco LM, Giliani
S, Zhang K, Alazami AM, Dobbs AK, Masneri S, Joshi A,
Otaizo-Carrasquero F, et al: PAX1 is essential for development and
function of the human thymus. Sci Immunol. 5:eaax10362020.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wu W, Kong X, Jia Y, Jia Y, Ou W, Dai C,
Li G and Gao R: An overview of PAX1: Expression, function and
regulation in development and diseases. Front Cell Dev Biol.
10:10511022022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Su PH, Lai HC, Huang RL, Chen LY, Wang YC,
Wu TI, Chan MWY, Liao CC, Chen CW, Lin WY and Chang CC: Paired
Box-1 (PAX1) activates multiple phosphatases and inhibits kinase
cascades in cervical cancer. Sci Rep. 9:91952019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Li X, Zhou X, Zeng M, Zhou Y, Zhang Y,
Liou YL and Zhu H: Methylation of PAX1 gene promoter in the
prediction of concurrent chemo-radiotherapy efficacy in cervical
cancer. J Cancer. 12:5136–5143. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Yang W, Zhang Z, Li L, Zhang K, Xu Y, Xia
M, Zhou J, Gong Y, Chen J and Gong K: ZNF582 overexpression
restrains the progression of clear cell renal cell carcinoma by
enhancing the binding of TJP2 and ERK2 and inhibiting ERK2
phosphorylation. Cell Death Dis. 14:2122023. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Li N, He Y, Mi P and Hu Y: ZNF582
methylation as a potential biomarker to predict cervical
intraepithelial neoplasia type III/worse: A meta-analysis of
related studies in Chinese population. Medicine (Baltimore).
98:e142972019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Huang J, Wang G, Tang J, Zhuang W, Wang
LP, Liou YL, Liu YZ, Zhou HH and Zhu YS: DNA Methylation Status of
PAX1 and ZNF582 in esophageal squamous cell carcinoma. Int J
Environ Res Public Health. 14:2162017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Huang RL, Chang CC, Su PH, Chen YC, Liao
YP, Wang HC, Yo YT, Chao TK, Huang HC, Lin CY, et al: Methylomic
Analysis Identifies Frequent DNA Methylation of Zinc Finger Protein
582 (ZNF582) in Cervical Neoplasms. PLoS One. 7:e410602012.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wu NYY, Zhang X, Chu T, Zhu S, Deng Y,
Zhou Y, Wang Y, Zhao X, Liu L, Fang C, et al: High methylation of
ZNF582 in cervical adenocarcinoma affects radiosensitivity and
prognosis. Ann Transl Med. 7:3282019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Yuan T, Edelmann D, Fan Z, Alwers E,
Kather JN, Brenner H and Hoffmeister M: Machine learning in the
identification of prognostic DNA methylation biomarkers among
patients with cancer: A systematic review of epigenome-wide
studies. Artif Intell Med. 143:1025892023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Ma JH, Huang Y, Liu LY and Feng Z: An
8-gene DNA methylation signature predicts the recurrence risk of
cervical cancer. J Int Med Res. 49:030006052110184432021.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Cech TR and Steitz JA: The noncoding RNA
revolution-trashing old rules to forge new ones. Cell. 157:77–94.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang Y, Weng Q, Ge J, Zhang X, Guo J and
Ye G: tRNA-derived small RNAs: Mechanisms and potential roles in
cancers. Genes Dis. 9:1431–1442. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Shi J, Zhang Y, Tan D, Zhang X, Yan M,
Zhang Y, Franklin R, Shahbazi M, Mackinlay K, Liu S, et al:
PANDORA-seq expands the repertoire of regulatory small RNAs by
overcoming RNA modifications. Nat Cell Biol. 23:424–436. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Mendell JT: MicroRNAs: Critical regulators
of development, cellular physiology and malignancy. Cell Cycle.
4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhang J, Chen B, Gan C, Sun H, Zhang J and
Feng L: A Comprehensive Review of Small Interfering RNAs (siRNAs):
Mechanism, therapeutic targets, and delivery strategies for cancer
therapy. Int J Nanomedicine. 18:7605–7635. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Matera AG, Terns RM and Terns MP:
Non-coding RNAs: lessons from the small nuclear and small nucleolar
RNAs. Nat Rev Mol Cell Biol. 8:209–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Meng X, Li X, Zhang P, Wang J, Zhou Y and
Chen M: Circular RNA: An emerging key player in RNA world. Brief
Bioinform. 18:547–557. 2017.
|
|
121
|
Mattick JS, Amaral PP, Carninci P,
Carpenter S, Chang HY, Chen LL, Chen R, Dean C, Dinger ME,
Fitzgerald KA, et al: Long non-coding RNAs: Definitions, functions,
challenges and recommendations. Nat Rev Mol Cell Biol. 24:430–447.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Fort V, Khelifi G and Hussein SMI: Long
non-coding RNAs and transposable elements: A functional
relationship. Biochim Biophys Acta Mol Cell Res. 1868:1188372021.
View Article : Google Scholar
|
|
123
|
Ozata DM, Gainetdinov I, Zoch A, O'Carroll
D and Zamore PD: PIWI-interacting RNAs: Small RNAs with big
functions. Nat Rev Genet. 20:89–108. 2019. View Article : Google Scholar
|
|
124
|
Abramowicz A and Story MD: The long and
short of It: The emerging roles of non-coding RNA in small
extracellular vesicles. Cancers (Basel). 12:14452020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Hahne JC, Lampis A and Valeri N: Vault
RNAs: Hidden gems in RNA and protein regulation. Cell Mol Life Sci.
78:1487–1499. 2021. View Article : Google Scholar :
|
|
126
|
Fan CM, Wang JP, Tang YY, Zhao J, He SY,
Xiong F, Guo C, Xiang B, Zhou M, Li XL, et al: circMAN1A2 could
serve as a novel serum biomarker for malignant tumors. Cancer Sci.
110:2180–2188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Toden S, Zumwalt TJ and Goel A: Non-coding
RNAs and potential therapeutic targeting in cancer. Biochim Biophys
Acta Rev Cancer. 1875:1884912021. View Article : Google Scholar :
|
|
128
|
Bo H, Fan L, Gong Z, Liu Z, Shi L, Guo C,
Guo C, Li X, Liao Q, Zhang W, et al: Upregulation and
hypomethylation of lncRNA AFAP1-AS1 predicts a poor prognosis and
promotes the migration and invasion of cervical cancer. Oncol Rep.
41:2431–2439. 2019.PubMed/NCBI
|
|
129
|
Xie M, Ma L, Xu T, Pan Y, Wang Q, Wei Y
and Shu Y: Potential regulatory roles of MicroRNAs and Long
Noncoding RNAs in Anticancer Therapies. Mol Ther Nucleic Acids.
13:233–243. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lampropoulou DI, Pliakou E, Aravantinos G,
Filippou D and Gazouli M: The Role of Exosomal Non-Coding RNAs in
colorectal cancer drug resistance. Int J Mol Sci. 23:14732022.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Fabbri M, Paone A, Calore F, Galli R,
Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, et al:
MicroRNAs bind to Toll-like receptors to induce prometastatic
inflammatory response. Proc Natl Acad Sci USA. 109:E2110–E2116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Yang W, Chendrimada TP, Wang Q, Higuchi M,
Seeburg PH, Shiekhattar R and Nishikura K: Modulation of microRNA
processing and expression through RNA editing by ADAR deaminases.
Nat Struct Mol Biol. 13:13–21. 2006. View Article : Google Scholar
|
|
133
|
Zou K, Yang E, Cui T and Li Z: Circulating
miR-326 could serve as a predictive biomarker for response to
neoadjuvant chemotherapy in locally advanced cervical cancer. Front
Oncol. 12:10367102022. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Hu X, Schwarz JK, Lewis JS Jr, Huettner
PC, Rader JS, Deasy JO, Grigsby PW and Wang X: A microRNA
expression signature for cervical cancer prognosis. Cancer Res.
70:1441–1448. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Pedroza-Torres A, Fernández-Retana J,
Peralta-Zaragoza O, Jacobo-Herrera N, Cantú de Leon D, Cerna-Cortés
JF, Lopez-Camarillo C and Pérez-Plasencia C: A microRNA expression
signature for clinical response in locally advanced cervical
cancer. Gynecol Oncol. 142:557–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wang Q, Qin J, Chen A, Zhou J, Liu J,
Cheng J, Qiu J and Zhang J: Downregulation of microRNA-145 is
associated with aggressive progression and poor prognosis in human
cervical cancer. Tumour Biol. 36:3703–3708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Fekete JT, Welker Á and Győrffy B: miRNA
expression signatures of therapy response in squamous cell
carcinomas. Cancers (Basel). 13:632020. View Article : Google Scholar
|
|
138
|
Wei H, Wen-Ming C and Jun-Bo J: Plasma
miR-145 as a novel biomarker for the diagnosis and radiosensitivity
prediction of human cervical cancer. J Int Med Res. 45:1054–1060.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Shi M, Du L, Liu D, Qian L, Hu M, Yu M,
Yang Z, Zhao M, Chen C, Guo L, et al: Glucocorticoid regulation of
a novel HPV-E6-p53-miR-145 pathway modulates invasion and therapy
resistance of cervical cancer cells. J Pathol. 228:148–157. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Liu M, An J, Huang M, Wang L, Tu B, Song
Y, Ma K, Wang Y, Wang S, Zhu H, et al: MicroRNA-492 overexpression
involves in cell proliferation, migration, and radiotherapy
response of cervical squamous cell carcinomas. Mol Carcinog.
57:32–43. 2018. View Article : Google Scholar
|
|
141
|
Barik S, Mitra S, Suryavanshi M, Dewan A,
Kaur I, Kumar D, Mishra M and Vishwakarma G: To study the role of
pre-treatment microRNA (micro ribonucleic acid) expression as a
predictor of response to chemoradiation in locally advanced
carcinoma cervix. Cancer Rep. 4:e13482021. View Article : Google Scholar
|
|
142
|
Wei W and Liu C: Prognostic and predictive
roles of microRNA-411 and its target STK17A in evaluating
radiotherapy efficacy and their effects on cell migration and
invasion via the p53 signaling pathway in cervical cancer. Mol Med
Rep. 21:267–281. 2020.
|
|
143
|
Zuccherato LW, Machado CMT, Magalhães WCS,
Martins PR, Campos LS, Braga LC, Teixeira-Carvalho A, Martins-Filho
OA, Franco TMRF, Paula SOC, et al: Cervical Cancer Stem-Like Cell
Transcriptome Profiles Predict Response to Chemoradiotherapy. Front
Oncol. 11:6393392021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Hasanzadeh M, Movahedi M, Rejali M, Maleki
F, Moetamani-Ahmadi M, Seifi S, Hosseini Z, Khazaei M, Amerizadeh
F, Ferns GA, et al: The potential prognostic and therapeutic
application of tissue and circulating microRNAs in cervical cancer.
J Cell Physiol. 234:1289–1294. 2019. View Article : Google Scholar
|
|
145
|
Ravegnini G, Gorini F, Dondi G, Tesei M,
De Crescenzo E, Morganti AG, Hrelia P, De Iaco P, Angelini S and
Perrone AM: Emerging Role of MicroRNAs in the therapeutic response
in cervical cancer: A systematic review. Front Oncol.
12:8479742022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Liu C and Wang R: The roles of hedgehog
signaling pathway in radioresistance of cervical cancer. Dose
Response. 17:15593258198852932019. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Fang F, Guo C, Zheng W, Wang Q and Zhou L:
Exosome-Mediated Transfer of miR-1323 from Cancer-Associated
Fibroblasts Confers Radioresistance of C33A Cells by Targeting
PABPN1 and Activating Wnt/β-Catenin signaling pathway in cervical
cancer. Reprod Sci. 29:1809–1821. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Che Y, Li Y, Zheng F, Zou K, Li Z, Chen M,
Hu S, Tian C, Yu W, Guo W, et al: TRIP4 promotes tumor growth and
metastasis and regulates radiosensitivity of cervical cancer by
activating MAPK, PI3K/AKT, and hTERT signaling. Cancer Lett.
452:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wen X, Liu S, Sheng J and Cui M: Recent
advances in the contribution of noncoding RNAs to cisplatin
resistance in cervical cancer. PeerJ. 8:e92342020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Sun Y, Feng Y, Zhang G and Xu Y: The
endonuclease APE1 processes miR-92b formation, thereby regulating
expression of the tumor suppressor LDLR in cervical cancer cells.
Ther Adv Med Oncol. 11:17588359198558592019. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yang F, Guo L, Cao Y, Li S, Li J and Liu
M: MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer
Cells and Modulation of Cellular Energy Homeostasis by Regulating
the Expression of the PARP-1 and BCL2 Genes. Med Sci Monit.
24:6506–6516. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
St Laurent G, Wahlestedt C and Kapranov P:
The Landscape of long noncoding RNA classification. Trends Genet.
31:239–251. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Luo F, Wen Y, Zhou H and Li Z: Roles of
long non-coding RNAs in cervical cancer. Life Sci. 256:1179812020.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chandra Gupta S and Nandan Tripathi Y:
Potential of long non-coding RNAs in cancer patients: From
biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967.
2017. View Article : Google Scholar
|
|
155
|
Zhang P, Wu W, Chen Q and Chen M:
Non-Coding RNAs and their Integrated Networks. J Integr Bioinform.
16:201900272019. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Ma L, Bajic VB and Zhang Z: On the
classification of long non-coding RNAs. RNA Biol. 10:925–933. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zhang W, Wu Q, Liu Y, Wang X, Ma C and Zhu
W: LncRNA HOTAIR promotes chemoresistance by facilitating
epithelial to mesenchymal transition through miR-29b/PTEN/PI3K
signaling in cervical cancer. Cells Tissues Organs. 211:16–29.
2022. View Article : Google Scholar
|
|
158
|
Zhou Y, Wang Y, Lin M, Wu D and Zhao M:
LncRNA HOTAIR promotes proliferation and inhibits apoptosis by
sponging miR-214-3p in HPV16 positive cervical cancer cells. Cancer
Cell Int. 21:4002021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Zhou M, Liu L, Wang J and Liu W: The role
of long noncoding RNAs in therapeutic resistance in cervical
cancer. Front Cell Dev Biol. 10:10609092022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Zhang H, Fang C, Feng Z, Xia T, Lu L, Luo
M, Chen Y, Liu Y and Li Y: The Role of LncRNAs in the regulation of
radiotherapy sensitivity in cervical cancer. Front Oncol.
12:8968402022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Li N, Meng DD, Gao L, Xu Y, Liu PJ, Tian
YW, Yi ZY, Zhang Y, Tie XJ and Xu ZQ: Overexpression of HOTAIR
leads to radioresistance of human cervical cancer via promoting
HIF-1α expression. Radiat Oncol. 13:2102018. View Article : Google Scholar
|
|
162
|
Liu S, Zhang M and Qu P: Expression level
and clinical significance of HOX transcript antisense intergenic
RNA in cervical cancer: A meta-analysis. Sci Rep. 6:380472016.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Lu H, He Y, Lin L, Qi Z, Ma L, Li L and Su
Y: Long non-coding RNA MALAT1 modulates radiosensitivity of HR-HPV+
cervical cancer via sponging miR-145. Tumour Biol. 37:1683–1691.
2016. View Article : Google Scholar
|
|
164
|
Gao J, Liu L, Li G, Cai M, Tan C, Han X
and Han L: LncRNA GAS5 confers the radio sensitivity of cervical
cancer cells via regulating miR-106b/IER3 axis. Int J Biol
Macromol. 126:994–1001. 2019. View Article : Google Scholar
|
|
165
|
Fang X, Zhong G, Wang Y, Lin Z, Lin R and
Yao T: Low GAS5 expression may predict poor survival and cisplatin
resistance in cervical cancer. Cell Death Dis. 11:5312020.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Ge X, Gu Y, Li D, Jiang M, Zhao S, Li Z
and Liu S: Knockdown of lncRNA PCAT1 Enhances Radiosensitivity of
Cervical Cancer by Regulating miR-128/GOLM1 Axis. Onco Targets
Ther. 13:10373–10385. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Belousova EA, Filipenko ML and Kushlinskii
NE: Circular RNA: New regulatory molecules. Bull Exp Biol Med.
164:803–815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Chen LL and Yang L: Regulation of circRNA
biogenesis. RNA Biol. 12:381–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Guttman M, Russell P, Ingolia NT, Weissman
JS and Lander ES: Ribosome profiling provides evidence that large
noncoding RNAs do not encode proteins. Cell. 154:240–251. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Li LJ, Leng RX, Fan YG, Pan HF and Ye DQ:
Translation of noncoding RNAs: Focus on lncRNAs, pri-miRNAs, and
circRNAs. Exp Cell Res. 361:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Wu P, Mo Y, Peng M, Tang T, Zhong Y, Deng
X, Xiong F, Guo C, Wu X, Li Y, et al: Emerging role of
tumor-related functional peptides encoded by lncRNA and circRNA.
Mol Cancer. 19:222020. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Wang F, Nazarali AJ and Ji S: Circular
RNAs as potential biomarkers for cancer diagnosis and therapy. Am J
Cancer Res. 6:1167–1176. 2016.PubMed/NCBI
|
|
173
|
Zhang N, Nan A, Chen L, Li X, Jia Y, Qiu
M, Dai X, Zhou H, Zhu J, Zhang H and Jiang Y: Circular RNA
circSATB2 promotes progression of non-small cell lung cancer cells.
Mol Cancer. 19:1012020. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zhou SY, Chen W, Yang SJ, Xu ZH, Hu JH,
Zhang HD, Zhong SL and Tang JH: The emerging role of circular RNAs
in breast cancer. Biosci Rep. 39:BSR201906212019. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Ruan H, Xiang Y, Ko J, Li S, Jing Y, Zhu
X, Ye Y, Zhang Z, Mills T, Feng J, et al: Comprehensive
characterization of circular RNAs in ~ 1000 human cancer cell
lines. Genome Med. 11:552019. View Article : Google Scholar
|
|
176
|
Enuka Y, Lauriola M, Feldman ME, Sas-Chen
A, Ulitsky I and Yarden Y: Circular RNAs are long-lived and display
only minimal early alterations in response to a growth factor.
Nucleic Acids Res. 44:1370–1383. 2016. View Article : Google Scholar :
|
|
177
|
Han B, Chao J and Yao H: Circular RNA and
its mechanisms in disease: From the bench to the clinic. Pharmacol
Ther. 187:31–44. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Li Z, Huang C, Bao C, Chen L, Lin M, Wang
X, Zhong G, Yu B, Hu W, Dai L, et al: Exon-intron circular RNAs
regulate transcription in the nucleus. Nat Struct Mol Biol.
22:256–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Hussen BM, Honarmand Tamizkar K, Hidayat
HJ, Taheri M and Ghafouri-Fard S: The role of circular RNAs in the
development of hepatocellular carcinoma. Pathol Res Pract.
223:1534952021. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Pan G, Mao A, Liu J, Lu J, Ding J and Liu
W: Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast
cancer progression through targeting miR-326/TFF1 signalling. Cell
Prolif. 53:e127202020. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ,
Shi GM, Cai JB and Ke AW: Cancer cell-derived exosomal circUHRF1
induces natural killer cell exhaustion and may cause resistance to
anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer.
19:1102020. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Sun G, Li Z, He Z, Wang W, Wang S, Zhang
X, Cao J, Xu P, Wang H, Huang X, et al: Circular RNA MCTP2 inhibits
cisplatin resistance in gastric cancer by miR-99a-5p-mediated
induction of MTMR3 expression. J Exp Clin Cancer Res. 39:2462020.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan
L, Andrews R, Zhong W, Zhang X, Song E and Gong C: Circular RNA
hsa_circ_001783 regulates breast cancer progression via sponging
miR-200c-3p. Cell Death Dis. 10:552019. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Luo YH, Yang YP, Chien CS, Yarmishyn AA,
Ishola AA, Chien Y, Chen YM, Huang TW, Lee KY, Huang WC, et al:
Plasma Level of Circular RNA hsa_circ_0000190 Correlates with tumor
progression and poor treatment response in advanced lung cancers.
Cancers (Basel). 12:17402020. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Diallo LH, Tatin F, David F, Godet AC,
Zamora A, Prats AC, Garmy-Susini B and Lacazette E: How are
circRNAs translated by non-canonical initiation mechanisms?
Biochimie. 164:45–52. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Pamudurti NR, Bartok O, Jens M,
Ashwal-Fluss R, Stottmeister C, Ruhe L, Hanan M, Wyler E,
Perez-Hernandez D, Ramberger E, et al: Translation of CircRNAs. Mol
Cell. 66:9–21.e7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Zhang X and Zheng X: Hsa_circ_0001495
contributes to cervical cancer progression by targeting
miR-526b-3p/TMBIM6/mTOR axis. Reprod Biol. 22:1006482022.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Xie H, Wang J and Wang B: Circular RNA
Circ_0003221 promotes cervical cancer progression by regulating
miR-758-3p/CPEB4 Axis. Cancer Manag Res. 13:5337–5350. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Ji F, Du R, Chen T, Zhang M, Zhu Y, Luo X
and Ding Y: Circular RNA circSLC26A4 accelerates cervical cancer
progression via miR-1287-5p/HOXA7 axis. Mol Ther Nucleic Acids.
19:413–420. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Wang YM, Huang LM, Li DR, Shao JH, Xiong
SL, Wang CM and Lu SM: Hsa_circ_0101996 combined with
hsa_circ_0101119 in peripheral whole blood can serve as the
potential biomarkers for human cervical squamous cell carcinoma.
Int J Clin Exp Pathol. 10:11924–11931. 2017.PubMed/NCBI
|
|
191
|
Li N, Liu J and Deng X: Identification of
a novel circRNA, hsa_circ_0065898, that regulates tumor growth in
cervical squamous cell carcinoma. Transl Cancer Res. 10:47–56.
2021. View Article : Google Scholar
|
|
192
|
Zhang X, Yang S, Chen W, Dong X, Zhang R,
Ye H, Ye H, Mei X, Liu H, Fang Y and He C: Circular RNA circYPEL2:
A novel biomarker in cervical cancer. Genes (Basel). 13:382021.
View Article : Google Scholar
|
|
193
|
Wu P, Qin J, Liu L, Tan W, Lei L and Zhu
J: circEPSTI1 promotes tumor progression and cisplatin resistance
via upregulating MSH2 in cervical cancer. Aging (Albany NY).
14:5406–5416. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Zhao Y, Lan Y, Chi Y, Yang B and Ren C:
Downregulation of Circ-CEP128 enhances the paclitaxel sensitivity
of cervical cancer through regulating miR-432-5p/MCL1. Biochem
Genet. 60:2346–2363. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Dong M, Li P, Xie Y, Wang Z and Wang R:
CircMYBL2 regulates the resistance of cervical cancer cells to
paclitaxel via miR -665-dependent regulation of EGFR. Drug Dev Res.
82:1193–1205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Zhao X, Dong W, Luo G, Xie J, Liu J and Yu
F: Silencing of hsa_circ_0009035 suppresses cervical cancer
progression and enhances radiosensitivity through MicroRNA
889-3p-Dependent regulation of HOXB7. Mol Cell Biol.
41:e00631202021. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Cho O, Chun M, Oh YT, Noh OK, Chang SJ,
Ryu HS and Lee EJ: Prognostic implication of simultaneous anemia
and lymphopenia during concurrent chemoradiotherapy in cervical
squamous cell carcinoma. Tumour Biol. 39:10104283177331442017.
View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Leetanaporn K and Hanprasertpong J:
Predictive value of the hemoglobin-albumin-lymphocyte-platelet
(HALP) index on the oncological outcomes of locally advanced
cervical cancer patients. Cancer Manag Res. 14:1961–1972. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Tang Z, Zeng M, Wang X, Guo C, Yue P,
Zhang X, Lou H, Chen J, Mu D, Kong D, et al: Synthetic lethality
between TP53 and ENDOD1. Nat Commun. 13:28612022. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Lyu J, Yang EJ, Zhang B, Wu C, Pardeshi L,
Shi C, Mou PK, Liu Y, Tan K and Shim JS: Synthetic lethality of RB1
and aurora A is driven by stathmin-mediated disruption of
microtubule dynamics. Nat Commun. 11:51052020. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Pfister SX, Markkanen E, Jiang Y, Sarkar
S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP,
Drobnitzky N, et al: Inhibiting WEE1 Selectively Kills Histone
H3K36me3-Deficient Cancers by dNTP Starvation. Cancer Cell.
28:557–568. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Sauerbrei W, Haeussler T, Balmford J and
Huebner M: Structured reporting to improve transparency of analyses
in prognostic marker studies. BMC Med. 20:1842022. View Article : Google Scholar : PubMed/NCBI
|
